Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody

Research output: Contribution to journalArticle

Abstract

Recombinant activated factor VII (rFVIIa) was used before and after inguinal hernioplasty to prevent bleeding in a patient with hemophilia A complicated by a high-potency antifactor VIII inhibitor. rFVIIa (75 (µg/kg) was given before and after surgery, first by bolus infusions at intervals of 2–3 h for 47 h and then by continuous intravenous infusion at a rate of 38 µg/h for an additional period of 12 h. Although no undue bleeding was observed during and for the first 26 h after surgery, the patient subsequently developed wound bleeding and hematomas that necessitated blood transfusion and infusion of porcine factor VIII. This case indicates that rFVIIa is not always successful in patients with antifactor VIII inhibitor and that more experience is needed to establish the optimal doses at surgery.

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalPathophysiology of Haemostasis and Thrombosis
Volume21
Issue number1
DOIs
Publication statusPublished - 1991

Keywords

  • Factor vii
  • Hemophilia
  • Porcine factor viii
  • Recombinant activated factor vii

ASJC Scopus subject areas

  • Hematology
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody'. Together they form a unique fingerprint.

  • Cite this